Physician profile
Mark D Allison
NPI 1164471223
$2,421.75
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $499 · 2021: $665 · 2022: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $326.37 | 2019-2022 | |
| Novo Nordisk INC | $310.86 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.89 | 2019-2022 | |
| Pfizer INC. | $229.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $178.82 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.08 | 2019-2022 | |
| Glaxosmithkline, LLC. | $110.26 | 2019-2022 | |
| Abbvie INC. | $96.88 | 2020-2022 | |
| Amgen INC. | $93.51 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $81.91 | 2019-2021 | |
| Lilly USA, LLC | $80.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.23 | 2019-2022 | |
| Allergan, INC. | $56.37 | 2019-2020 | |
| Eisai INC. | $43.92 | 2020-2021 | |
| Boston Scientific Corporation | $39.93 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.08 | 2019-2020 | |
| Esperion Therapeutics, INC. | $34.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.81 | 2019-2020 | |
| Abbott Laboratories | $28.18 | 2022 | |
| Breathe Technologies, INC. | $27.53 | 2019 | |
| Melinta Therapeutics, LLC | $27.06 | 2019 | |
| Ironwood Pharmaceuticals, INC | $25.80 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.67 | 2019 | |
| Daiichi Sankyo INC. | $22.91 | 2019 | |
| Vivus LLC | $16.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.18 | 2022 | |
| Optos, INC. | $12.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.12 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.